Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (705)	8/2/1998 9:36:00 AM
From: Robert K.	Respond to of 3202

I agree, public domain. I also agree in a bit of courtesey. Thanks for the approval.

To: Rocketman who wrote (705)	8/11/1998 3:42:00 PM
From: Don S.Boller	Respond to of 3202

Rocketman: JUST THOUGHT YOU LIKE TO KNOW THAT... the latest issue of "Red Herring" - No. 58 - list INCY as the ONLY bio in their 50 public technology companies for 1998. Best, Don

To: Rocketman who wrote (705)	8/17/1998 2:04:00 AM
From: Vector1	Read Replies (2) \| Respond to of 3202

Incyte to Acquire Hexagen UK Company Brings Genetics Technology to Newly Formed Incyte Pharmacogenetics Business Unit PALO ALTO, Calif., Aug. 17 -- Incyte Pharmaceuticals, Inc., (Nasdaq: INCY) announced today that it has entered into an agreement to acquire Hexagen plc, a privately held company based in Cambridge, England. Hexagen has developed leading edge technology for rapid discovery of single nucleotide polymorphisms (SNPs). The identification of SNPs is of major technological and commercial significance to the pharmaceutical industry because they are believed to be important in determining an individual patient's susceptibility to disease or response to drugs. Hexagen will be a part of Incyte's new pharmacogenetics business unit, Incyte Genetics, whose formation also was announced today. Under the terms of the agreement, Incyte will offer, in exchange for all of Hexagen's outstanding capital stock, $5 million in cash and approximately 1.0 million shares of Incyte common stock. In addition, Incyte will assume Hexagen's stock options which, if exercised, would amount to approximately 0.1 million